Clinical trials: Type 1 or Type 2 Diabetes
Type 1 Diabetes, Type 2 Diabetes
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
The purpose of this study is to demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring (GM) System interstitial glucose results against Reader capillary Blood Glucose (BG) reference using the Consensus Error…
- Trial name
- NCT02073058
- Testing
- No treatment
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Abbott Diabetes Care
Type 2 Diabetes Mellitus
Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin
The purposes of this study are to determine: 1. If patients taking insulin lispro LM with metformin will have better overall control of their blood sugar than patients taking a long acting insulin comparator with metformin. 2.
- Trial name
- NCT00036504
- Testing
- Insulin Lispro low mixture
- Where
- 13 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
Feasibility Trial of the Bios Device for Continuous Glucose Monitoring
The study is an open-label, prospective, within-subject comparison of the Bios device readings versus venous blood sample glucose readings, glucose readings from a Dexcom CGM and an SMBG device in subjects previously diagnosed…
- Trial name
- NCT04226846
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- GraphWear Technologies Inc.
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Obesity and Overweight
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes
This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).
- Trial name
- NCT06845943
- Testing
- HCR-188
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Helicore Biopharma, Inc.
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
Type 2 Diabetes
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
The aim of this trial is to compare the efficacy and safety of HR17031 versus INS068 and SHR20004 in subjects with type 2 diabetes.
- Trial name
- NCT05333835
- Testing
- HR17031 injection, INS068 injection, SHR20004 injection
- Where
- China
- Volunteers
- 455 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months.
- Trial name
- CAN-TREAT (NCT03674866)
- Testing
- Insulin degludec
- Where
- 32 sites in Canada
- Volunteers
- 662 people
- Sponsor
- Novo Nordisk A/S
Melanoma
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study.
- Trial name
- NCT04305054
- Testing
- Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab
- Where
- 60 sites in United States, Argentina and 12 more
- Volunteers
- 335 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
Comparison of 2 NovoFine® Needles on the Reflux of Insulin
This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and NovoFine® 8 x 0.30 mm on reflux of insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Delivery Systems
- Trial name
- NCT00872560
- Testing
- NovoFine® needle 6 mm, NovoFine® needle 8 mm
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00617565
- Testing
- biphasic insulin aspart, biphasic human insulin
- Where
- 6 sites in China
- Volunteers
- 219 people
- Sponsor
- Novo Nordisk A/S
Diabetes Type 2
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
This study will evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.
- Trial name
- NCT00461136
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Novartis
Type 1 or Type 2 Diabetes
Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring
From Jan 2022 to June 2022, 120 subjects (22-75 years of age, mean ±standard deviation [SD] of 53.20 ±14.49 years) with type 1 or type 2 diabetes participated in the study in P.R. China.
- Trial name
- NCT05995756
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Sinocare
Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose…
- Trial name
- NCT06406439
- Testing
- Smart Insulin Pen, Injection of bolus insulin via conventional therapy using insulin pen
- Where
- 9 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- G2e Co., Ltd
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant.
- Trial name
- NCT02806973
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Diabetic Foot Ulcer, Type 1 Diabetes Mellitus
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2…
- Conditions
- Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer
- Trial name
- NCT06810726
- Testing
- Platelet Rich Plasma
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Estar Medical dba Medical Technologies, LTD
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety While Using Levemir®
This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice conditions in Egypt.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00701155
- Testing
- insulin detemir
- Where
- Egypt
- Volunteers
- 3,593 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
- Trial name
- NCT00143247
- Testing
- Exubera® (inhaled insulin)
- Where
- 12 sites in United States
- Volunteers
- 173 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes, Type 2 Diabetes
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
The purpose of this study is to evaluate the safety and pancreas imaging properties of 18F-AV-133.
- Trial name
- NCT01515384
- Testing
- 18F-AV-133
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals